GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

GSK PLC (LSE:GSK, NYSE:GSK) has announced that its phase III FIRST-ENGOT-OV44 trial met its primary goal, or 'endpoint'. The study showed that the addition of Jemperli (dostarlimab) to platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, significantly improved progression-free survival (PFS) in first-line advanced ovarian cancer.

GSK's FIRST trial achieves progression-free survival milestone in advanced ovarian cancer

GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance improved survival in patients with advanced ovarian cancer without the disease getting worse in a late-stage trial.

GSK's cancer drugs meet progression-free survival goal in late-stage trial

The CHMP recommends marketing approval to GSK's Vocabria plus JNJ's Rekambys for treating HIV-1 infection in adolescents aged 12 years and older.

GSK Gets CHMP Nod for Expanded Use of HIV Combo & Jemperli

GSK PLC (LSE:GSK, NYSE:GSK) has announced significant progress in its oncology pipeline, achieving three milestones. The European Medicines Agency (EMA) has issued a positive opinion recommending the expanded approval of Jemperli (dostarlimab) with chemotherapy for first-line treatment of advanced or recurrent endometrial cancer.

GSK passes three significant milestones with new cancer drug given a double boost

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its sales and profits to improve.

GSK Stock Declines 20% in 3 Months: Should You Buy, Sell or Hold?

FOR IMMEDIATE RELEASE Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis

GSK PLC (LSE:GSK, NYSE:GSK) shares in New York rose Monday afternoon after it announced that its blood cancer drug Blenrep (belantamab mafodotin) significantly extended survival in a pivotal trial. The drug, combined with two other therapies, reduced the risk of death by 42% compared to a rival treatment from Johnson & Johnson (NYSE:JNJ), according to results presented at the American Society of Hematology's annual meeting.

GSK says blood cancer drug shows dramatic survival gains in key trial

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the risk of death by 42% in multiple myeloma, a common type of blood cancer, at or after first relapse compared to an existing treatment.

GSK's drug combo shown to cut risk of death by 42% in type of blood cancer

The FDA accepts GSK's regulatory filing seeking the expanded use of Nucala in COPD treatment for review.

FDA Accepts GSK's Filing for Expanded Use of Nucala in COPD

GSK expands the licensing deal with Zhifei to market its shingles vaccine in China for an additional eight years till 2034.

GSK Expands Vaccine Collaboration With Zhifei in China

GSK PLC (LSE:GSK, NYSE:GSK) has extended its partnership with Chongqing Zhifei Biological Products (Zhifei) to bring its shingles vaccine, Shingrix, to mainland China through 2034. The revised agreement builds on a previous three-year deal and includes exclusive rights for Zhifei to import, distribute, and promote Shingrix.

GSK extends vaccine partnership with Zhifei in China

GSK extended its collaboration with Zhifei to commercialize its shingles vaccine Shingrix in China until 2034.

GSK, China's Zhifei Expand Shingles Shot Collaboration

GSK said on Thursday it has expanded its agreement with China's Zhifei to explore a collaboration with the Chinese vaccines company on the British drugmaker's respiratory syncytial virus (RSV) vaccine, Arexvy.

GSK expands deal with China's Zhifei to explore RSV vaccine collaboration

The European Commission approves fully liquid presentation of GSK's meningococcal vaccine, Menveo, to protect against invasive meningococcal disease.

GSK Gets EC Nod for Liquid Version of Meningococcal Vaccine Menveo

GSK PLC (LSE:GSK, NYSE:GSK) has received approval from the European Commission for a new, fully liquid version of its Menveo vaccine, which protects against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W, and Y. This updated formulation eliminates the need for reconstitution before use, simplifying the vaccination process for healthcare providers.

GSK's receives European Commission green light for liquid form of key vaccine

The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.

FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma

The US Food and Drug Administration (FDA) has accepted GSK PLC (LSE:GSK, NYSE:GSK)'s application to review the use of Blenrep (belantamab mafodotin) in treating relapsed or refractory multiple myeloma, a blood cancer. If approved, Blenrep could be combined with bortezomib and dexamethasone (BorDex) or pomalidomide and dexamethasone (PomDex) for patients who have already undergone at least one prior therapy.

GSK submits multiple myeloma treatment for approval to the US regulator

GSK PLC (LSE:GSK, NYSE:GSK) has announced that Japan's Ministry of Health, Labour and Welfare has approved its RSV vaccine, Arexvy, for use in adults aged 50-59 at increased risk of severe RSV-related outcomes. The vaccine was previously approved in Japan for individuals aged 60 and older.

GSK's RSV vaccine gets greenlight in Japan

GSK said on Friday that its respiratory syncytial virus (RSV) vaccine has received approval in Japan for expanded use in adults aged between 50 and 59, who are at increased risk of severe RSV disease.

GSK's RSV vaccine gets Japan approval for adults aged 50 to 59

The GLISTEN study evaluating GSK's candidate, linerixibat, for treating cholestatic pruritus related to primary biliary cholangitis meets the primary endpoint.

GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study

The GSK share price has been in a strong freefall after peaking at 1,785p in September. Most recently, the GSK stock retreated for five consecutive weeks and reached its lowest level since October last year.

GSK share price is imploding: is it safe to buy the dip?

GSK PLC (LSE:GSK, NYSE:GSK)has reported positive results from its phase III trial of linerixibat, a drug being tested to treat relentless itching caused by primary biliary cholangitis (PBC). PBC is a rare autoimmune disease that damages the bile ducts and can lead to liver failure.

GSK trial shows promising results for treatment of persistent itch in rare liver disease

British drugmaker GSK said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmune liver disease.

GSK drug meets main goal in late-stage study to treat relentless itch

Johnson & Johnson

Eli Lilly

Merck

Moderna

Pfizer

Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. Department of Health and Human Services.

As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.

GSK plc (NYSE:GSK ) Guggenheim's Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Emma Walmsley - Chief Executive Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez I'm absolutely thrilled that this we're clearly going to have the best conversation in the fireside chat that we've had so far. Incredibly pleased to have Emma Walmsley here.

News for GlaxoSmithKline Stock (GSK)